Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2021-09-03 00:00:00 ET · period of report 2021-09-03 · accession 0000899243-21-035158 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-09-03 | 2021-09-03 | KYMR | Jacobs Bruce N. | CFO | S - Sale+OE | $60.12 | -10.0K | 7,256 | -58% | -$601.2K |
| D | 2021-09-03 | 2021-09-03 | KYMR | Jacobs Bruce N. | CFO | M - OptEx | $2.08 | -10.0K | 17.3K | -37% | -$20.8K |
| D | 2021-09-03 | 2021-09-03 | KYMR | Jacobs Bruce N. | CFO | A - Grant | $0.00 | -10.0K | 209.9K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-03 | S | D | 8,500 | $60.05 | 8,756 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.41 to $60.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 2 | Common | Common Stock | 2021-09-03 | S | D | 1,500 | $60.50 | 7,256 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.42 to $60.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 3 | Common | Common Stock | 2021-09-03 | M | D | 10,000 | $2.08 | 17,256 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2021-09-03 | A | D | 10,000 | $0.00 | 209,899 | D | $2.08 · — to 2029-08-28 | 10,000 Common Stock | (F4) Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. |